SLNO News and Press, Soleno Therapeutics Inc. From 05/02/24

2024-05-02 16:07:53 ET More on Soleno Therapeutics Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch Soleno Therapeutics GAAP EPS of -$0.33 misses by $0.07 Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings...

REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results from the Company&#x...

2024-04-29 16:02:16 ET Summary Soleno Therapeutics, Inc.'s New Drug Application filing of DCCR for the treatment of patients with Prader-Willi Syndrome expected by mid-2024. Ability to file NDA of DCCR for PWS was because of statistical significance achieved based on the primary e...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is one of today's top gainers. The company's shares have moved 34.88% on the day to $51.1. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of...

2024-04-29 11:11:00 ET Shares of Soleno Therapeutics (NASDAQ: SLNO) were skyrocketing 39.8% higher as of 10:51 a.m. ET on Monday. The huge gain came after the clinical-stage biopharmaceutical company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...

2024-04-29 10:02:54 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...

A look at the top 10 most actives in the United States SoFi Technologies Inc. (SOFI) fell 9.7% to $7.1068 on volume of 45,729,887 shares Tesla Inc. (TSLA) rose 11.6% to $187.7701 on volume of 45,057,076 shares Collective Audience Inc. (CAUD) rose 71.6% to $0.669199 on volume of 34,955,653...

2024-04-29 08:29:50 ET More on Soleno Therapeutics Soleno Therapeutics GAAP EPS of -$0.33 misses by $0.07 Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings data for Soleno Therapeutics Financial information for Soleno Therapeutics...

First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY, Calif., April 29, 2024 (GLOBE NEW...

2024-03-07 10:01:04 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...